Immuron’s shares surge on demonstrating proof of concept for liver drug candidate

Immuron Limited’s (ASX:IMC) (NASDAQ:IMRN) IMM-124E has demonstrated a statistically significant reduction in serum lipopolysaccharide (LPS) levels, a major factor in liver inflammation.

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.